Optimizing Patient Outcomes
Accurate Timeline Communication
Communicating a realistic timeline to your patient can make a significant difference in their overall treatment outcome. Treating Peyronie's disease, plantar fibromatosis, and Dupuytren's contracture with Transdermal Verapamil 15% Gel is a gradual process. In Peyronie's disease and plantar fibromatosis studies, a marked improvement in symptoms at the 9 month interval over the 3 month interval of treatment indicates the importance of patients' consistent use of the medication over time. The timeline below is indicative of what has been observed in studies as well as patient reported outcomes from the more than 13,000 patients PDLabs has worked with.
These results are typical with patients' compliance with twice a day dosing.
Proper Application
In order to achieve the best possible results with Transdermal Verapamil 15% Gel it is critical that patients are compliant with twice a day dosing. This allows for a sustained level of drug to depot in the epidermis and release to the lesion as demonstrated in the skin penetration study. Patients should apply the medication twice a day as follows:
Peyronie's Disease
- Measure a 0.5ml dose with the provided dosimeters
- Apply to the entire penile shaft (excluding the glans)
- Thoroughly massage the medication into the skin (occlusion is not necessary)
Plantar Fibromatosis
- Measure a 1.0ml dose with the provided dosimeters
- Apply to the entire plantar fascia (patients are instructed to apply the medication from the ball of the foot to the front of the heel and the entire width of the foot)
- Thoroughly massage the medication into the skin (occlusion is not necessary)
Dupuytren's Disease
- Measure a 0.5ml dose with the provided dosimeters
- Apply to the entire palm and any affected fingers
- Thoroughly massage the medication into the skin (occlusion is not necessary)
Patients receive verbal as well as detailed written instructions that explain the proper application procedure.
Regimen Changes
Most patients will respond well to the standard dosing of 0.5ml, BID for Peyronie's disease and Dupuytren's disease or 1.0ml BID for plantar fibromatosis. In the event that patients are not responding at the completion of 90 days of compliant use, changing the patient to a different application regimen may be beneficial. In these cases, a PDLabs' pharmacist will contact the prescribing physician to discuss alternative doses that have had a positive effect or proven successful.